Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pranoot Tanpaiboon is active.

Publication


Featured researches published by Pranoot Tanpaiboon.


The application of clinical genetics | 2016

Role of elosulfase alfa in mucopolysaccharidosis IVA.

Debra S Regier; Pranoot Tanpaiboon

Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a striking skeletal phenotype, but does not negatively impact the intellect of the patient. MPS IVA has a phenotypic continuum that ranges from a severe and rapidly progressing form to a slowly progressive form. The clinical diagnosis is often made in the preschool years based on abnormal bone findings on physical examination and dysplasia on radiographic imaging. Supportive care has been the mainstay in caring for patients. Orthopedic physicians often form the core of the care team due to the early and severe skeletal abnormalities; however, systemic disease is common and requires aggressive monitoring and management. Interdisciplinary care teams often consist of medical geneticists, cardiologists, pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmologists. With the US Food and Drug Administration’s approval of elosulfase alfa, patients >5 years of age now have access to this medication from the time of diagnosis. The clinical trial with once weekly intravenous dosing (2.0 mg/kg per week) showed improvement in the 6-minute walk test. The composite end point analysis to evaluate the combining changes from baseline in 6-minute walk test, 3-minute stair climb test, and respiratory function showed that at a dose of 2.0 mg/kg per week, subjects performed better when compared to placebo. This indication was clinically meaningful in the treatment group. The treatment was generally well tolerated, and the uncommon infusion reactions responded well to traditional enzyme replacement therapy infusion reaction management algorithms. Currently, clinical trials are underway to determine the efficacy and safety in MPS IVA patients <5 years of age.


Archive | 2016

Mucopolysaccharidosis Type IVA

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 8. [Hip x-ray of a female...].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 6. [Lateral cervical spine x-ray of...].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 1. [Ulnar deviation of both wrists and joint enlargement in a male age 15 years with MPS IVA].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Table 2. [GALNS Pathogenic Variants Discussed in This GeneReview].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 3. [Pectus anomaly and short neck in a male age 15 years with MPS IVA].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 4. [Lateral view of chest showing severe pectus carinatum in a male age 15 years with MPS IVA].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Figure 5. [Severe genu valgum (knock-knee) in a male age 15 years with MPS IVA].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon


Archive | 2016

Table 1. [Molecular Genetic Testing Used in Mucopolysaccharidosis Type IVA].

Debra S Regier; Matthew Oetgen; Pranoot Tanpaiboon

Collaboration


Dive into the Pranoot Tanpaiboon's collaboration.

Researchain Logo
Decentralizing Knowledge